Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans.

What Was Tested

The paper reports a study of Glucagon, published as a randomized controlled trial.

Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain.

The researchers therefore tested whether these neuroprotective effects could relate to changes of glucose transport and consumption.

Who Took Part

According to the abstract, 10 men were involved.

By PubMed's age tags, the people studied were adults, men only.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

The men were allocated by chance, so the Glucagon group and the comparison group should start out alike.

Neither the men nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Glucagon group a baseline to be compared against.

In the crossover set-up each of the men took both Glucagon and the comparison in turn, acting as their own control.

What Was Measured

Topics PubMed links to this paper include Biological Transport, Blood Glucose, Blood-Brain Barrier, Brain, C-Peptide, Glucagon-Like Peptide 1 and Glucose.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon in 10 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2008 (Diabetes), a journal based in United States.

More context: the Glucagon compound page, all human trials.